glp-1 agonists muscle loss Current data suggest receptor do not have direct deleterious effects on beyond the lean mass typically seen with weight reduction. Observed declines in lean mass appear proportional to Anti-GLP-1R Antibody (A83537) brain-cognitive-support Subscription:3 months

glp-1 agonists muscle loss Current data suggest receptor do not have direct deleterious effects on beyond the lean mass typically seen with weight reduction. Observed declines in lean mass appear proportional to Anti-GLP-1R Antibody (A83537) brain-cognitive-support Subscription:3 months

Anti-GLP-1R Antibody (A83537)

The central nervous system activities of GLP-1 significantly impact hunger and food intake regulation via both central and peripheral pathways

brain-cognitive-support

Subscription:3 months

And with more than half of the global population (51% or over 4 billion people) predicted to be either overweight or living with obesity by 2035, investment in obesity drugs is forecast to rise by a compound annual growth rate of 35%–38% between 2023 and 2027.9,10 While some GLP-1 treatments currently in the pipeline are set to reach the market in oral tablet form, autoinjectors and pen injectors currently at the forefront of GLP-1 delivery will continue to deliver multiple patient benefits across this significantly expanded market segment